Modipafant

Drug Profile

Modipafant

Alternative Names: 60P 002; UK 80067

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer 60 Degrees Pharmaceuticals Australia; Pfizer
  • Class Antiasthmatics; Dihydropyridines; Imidazoles; Small molecules
  • Mechanism of Action Calcium channel antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dengue
  • Discontinued Asthma

Most Recent Events

  • 14 May 2018 60 Degree Pharmaceuticals plans a phase II trial for Dengue (60 Degrees pipeline, May 2018)
  • 11 Dec 2015 Modipafant licensed to Knight Therapeutics in Canada, Israel and Russia
  • 28 Sep 2015 Discontinued - Clinical-Phase-Unknown for Asthma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top